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Osteosarcoma is the most common primary malignant bone tumour with a high 
resistance to chemo- and radiotherapy. Hyperthermia is a well-established 
type of cancer treatment. However, the molecular changes and responses of 
osteosarcoma cells to hyperthermia are not well understood. Hypothermia 
has been proven to be protective in certain medical situations such as brain 
surgery, but there is no published study about its effect in bone cancer. 
According to literature, about 60% of all cancer patients take supplements 
without informing their oncologists during therapy. Little is known about 
the effect of antioxidants like berberine chloride on osteosarcoma cells, 
especially in combination with hyperthermia. Berberine is a natural alkaloid 
available in several traditional herbs, and it can help treat many pathological 
conditions. The overall objective of this study is to investigate the short- and 
long-term effects of various stages of hyper- and hypothermia on osteoblast-
like osteosarcoma cells and its underlying mechanism of action. It also seeks 
to study the long-term effect of a single short-term treatment with severe 
hyperthermia (45°C, 1 h) on osteosarcoma cells and its underlying causes. An 
additional objective is to investigate the effect of hyperthermia alone and in 
combination with berberine chloride on osteosarcoma cells and its underlying 
mechanisms. Osteoblast-like osteosarcoma cells (MG-63 cells) were treated 
with hyper- and hypothermia for short, medium and long-term periods. 
Some cells were also treated with berberine chloride and a combination of 
berberine chloride with mild, moderate, and severe hyperthermia. Severe 
hypothermia and hyperthermia showed a time-dependent toxicity; hence 
viability was reduced in a significant manner at all time points, whereas 
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mild hypothermia showed a protective effect. Severe hyperthermia induced 
significant DNA damage at all time points. Severe and mild hyperthermia 
(1 h) in the present study resulted in the downregulation of CIRBP, which 
may explain the significant cell death. Caspase-3/7, 8, and 9 showed very 
low activity at 12, 24 and 72 h post-treatment with severe hyperthermia due 
to RNA degradation and massive cell death. On the other hand, the effect 
of severe hyperthermia on the cytoskeleton was lethal at 12 h and onward. 
The long-term effect of severe hyperthermia (1 h at 45ºC and recovery at 
37ºC for 72 h) activates caspase-3/7, 4, 8, 9, and 12 in association with 
a significant reduction of Hsp90-alpha expression and induced apoptosis. 
Additionally, hyperthermia suppressed RANKL mRNA expression and 
elevated Osterix, whereas RUNX2 showed levels similar to untreated 
control. The changes in RANKL and Osterix expression in this study 
indicate that hyperthermia may be inducing differentiation of osteosarcoma. 
Berberine chloride (80 µg/ml) induced apoptosis in a significant manner. 
Mild hyperthermia (39°C) resulted in the attenuation of berberine chloride 
cytotoxicity against osteosarcoma cells in a significant way. All treatments 
of berberine, hyperthermia, and hyperthermia combination with berberine 
chloride induced apoptosis and suppressed enzymatic activity and mRNA 
expression of caspase-3/7, 8, and 9. In conclusion, severe hypothermia 
showed an anti-proliferative apoptotic effect; severe hyperthermia was more 
effective in bone cancer killing at 12 h and above, and mild hyperthermia 
attenuated the cytotoxicity of berberine chlori.
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Trabeculectomy is the gold standard procedure performed in glaucoma 
when topical medication and laser intervention fail to maintain the ideal 
intraocular pressure (IOP) of patient’s eye. However, excessive accumulation 
of extracellular matrix components (ECM) mediated by Tenon’s fibroblast 
(HTF) leads to significant cases of surgical failure. Anti-vascular endothelial 
growth factor (VEGF) has become the focus in current scar modulation 
strategy. Improved bleb morphology following trabeculectomy augmented 
with ranibizumab has been reported. However, mechanism of actions of 
ranibizumab on HTF is not well understood. Therefore, this in vitro study 
was conducted to elucidate mechanism of actions of ranibizumab on HTF. 
HTF used in this study were propagated from Tenon’s capsule obtained from 
patients undergoing trabeculectomy. Firstly, isolated and characterized HTF 
were treated with different concentrations of ranibizumab in serum and 
serum-free media for 24 and 48 hours and then HTF viability was measured 
using MTT assay. Then, HTF were extracted to measure the expression of 
collagen Type 1 (COL1A1), fibronectin (FN), transforming growth factor-β1 
and -β2 (TGF-β1 &TGF-β2) using qRT-PCR and ELISA. The experiment was 
followed with metabolomics profiling which was performed to identify the 
most significant metabolite regulated by ranibizumab. Finally, the expression 
of regulatory genes and proteins involved in the cell cycle regulation and 
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angiogenesis including p21, p53, CDK2, CDK4, PTEN, AKT1 and THBS1 
were measured by RT2 Profiler PCR Array and Western Blot. Findings 
from the MTT assay showed that ranibizumab at the concentration of 
0.5 mg/ml induce significant reduction in HTFs viability. The optimum 
degree of reduction was observed in serum-free media incubated for 48 
hours. Furthermore, results suggested that ranibizumab mediates the down-
regulation of COL1A1 and TGF-β1at gene level, but not at the protein level. 
No relevant changes were observed in FN and TGF-β2 mRNA level, but 
the proteins level was up-regulated. In metabolomics study, ranibizumab 
was shown to induce significant reduction in spermidine level. Therefore 
in subsequent experiment, ranibizumab effects were compared to DFMO, 
a potent irreversible inhibitor in spermidine synthesis. Findings show that 
ranibizumab exerts similar mechanism to DFMO in regulating spermidine 
expression by HTF, where it reduces PTEN, AKT1 and THBS1 expression. 
Moreover, ranibizumab administration increase p53 and p21 expression 
and reduces CDK2 and CDK4 expression. These observations suggest 
that ranibizumab might exert its anti-scarring property by enhancing the 
activities of p53 and p21, thus lead to reduction in CDK2 and CDK4. 
This shows that cell cycle of ranibizumab-treated HTF could be arrested, 
particularly at G1 phase.
